Crizotinib is used in the treatment of :
**Core Concept**
Crizotinib is a tyrosine kinase inhibitor that targets the anaplastic lymphoma kinase (ALK) gene, which is involved in the pathogenesis of certain types of cancer. The ALK gene is a fusion gene resulting from chromosomal rearrangements, leading to the formation of a constitutively active tyrosine kinase that drives tumor growth.
**Why the Correct Answer is Right**
Crizotinib works by inhibiting the ALK tyrosine kinase, thereby blocking the downstream signaling pathways that promote cell proliferation and survival. This results in the inhibition of tumor growth and induction of apoptosis in cancer cells harboring the ALK fusion gene. Crizotinib has been shown to be effective in treating non-small cell lung cancer (NSCLC) with ALK rearrangements, including those with the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion.
**Why Each Wrong Option is Incorrect**
**Option A:** Crizotinib is not primarily used to treat breast cancer. While tyrosine kinase inhibitors are used in the treatment of breast cancer, crizotinib is specifically targeted at ALK-positive tumors, which are not typically associated with breast cancer.
**Option B:** Crizotinib is not a chemotherapy agent. While it does induce apoptosis in cancer cells, its mechanism of action is through the inhibition of tyrosine kinase activity, rather than through the induction of DNA damage or disruption of microtubule function.
**Option C:** Crizotinib is not a monoclonal antibody. It is a small molecule tyrosine kinase inhibitor, which binds to the ATP-binding pocket of the ALK tyrosine kinase, rather than targeting a specific protein antigen.
**Option D:** Crizotinib is not used to treat gastrointestinal stromal tumors (GISTs). While tyrosine kinase inhibitors are used to treat GISTs, crizotinib is specifically targeted at ALK-positive tumors, which are not typically associated with GISTs.
**Clinical Pearl / High-Yield Fact**
Crizotinib is a paradigm example of targeted therapy in oncology, highlighting the importance of molecular profiling in identifying patients who are most likely to benefit from specific treatments. The development of crizotinib has also led to the discovery of other ALK inhibitors, such as alectinib and brigatinib, which are being explored in clinical trials.
**Correct Answer:** C. Non-small cell lung cancer (NSCLC) with ALK rearrangements.